Form 8-K - Current report:
SEC Accession No. 0001213900-19-005717
Filing Date
2019-04-03
Accepted
2019-04-03 16:32:17
Documents
8
Period of Report
2019-04-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 f8k040119_citiupharma.htm 8-K 40124
2 COMMON STOCK PURCHASE WARRANT f8k040119ex4-1_citiupharma.htm EX-4.1 111941
3 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT f8k040119ex4-2_citiupharma.htm EX-4.2 97617
4 OPINION OF WYRICK ROBBINS YATES & PONTON LLP f8k040119ex5-1_citiupharma.htm EX-5.1 6842
5 SECURITIES PURCHASE AGREEMENT f8k040119ex10-1_citiupharma.htm EX-10.1 255682
6 LETTER AGREEMENT f8k040119ex10-2_citiupharma.htm EX-10.2 50093
7 CITIUS ANNOUNCES $5.3 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET f8k040119ex99-1_citiupharma.htm EX-99.1 8594
8 GRAPHIC ex10-2_001.jpg GRAPHIC 6746
  Complete submission text file 0001213900-19-005717.txt   581732
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 19729424
SIC: 2834 Pharmaceutical Preparations